Bayer: elinzanetant data presented at congress
The German chemical and pharmaceutical group reports that both studies met all their primary endpoints, showing statistically significant reductions in the frequency and severity of vasomotor symptoms (hot flushes) compared with placebo.
Key secondary endpoints were also met, with demonstrated improvements in sleep disturbance and quality of life.
These results were presented at the annual meeting of the American College of Obstetricians and Gynecologists (ACOG) in San Francisco.
Elinzanetant has not yet received marketing approval, but Bayer plans to submit these data to health authorities with a view to obtaining marketing authorizations.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction